HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc. (OTCBB: HSTC) today announced the launch of a cognitive function product endorsed and recommended by Dr. Kyl Smith under a Joint Venture with Dalham, LLC (an affiliate company of The Health Network, Inc.). The Company intends to launch the new product on August 1, 2009. The new product will be named Focus-Up®.
Ron Howell, CEO/President stated, “With the North American Baby Boomer population standing at 80 million, one out of every three Americans will be age 50 or over by 2010. These facts, in conjunction with continued advances in age and condition-specific products and technologies bode well for the industry as a whole. There is an especially robust market for Focus-Up®, particularly among these older consumers. In fact, market research shows that this category will lead gains in its $20 billion industry in the US alone.”
Dr. Kyl Smith stated, “HST plans to mature the expansion and development of two unique product lines; a physician-formulated 'all natural' nutritional product line designed to address wellness challenges and provide preventative maintenance and support overall health; and a Medical Food line providing new and novel physician-based therapeutic approaches that positively impact patients with immune and degenerative disorders, who are in need of effective, well-tolerated treatments. This will allow HST to concentrate on the acquisition of patent applications and technologies that the company controls from formulation through to consumer application as well as integrating the educational process necessary to help patients understand the underlying need for good nutrition in achieving and maintaining optimum health.”
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and Wellness company that is developing and or acquiring a network of Wellness Centers worldwide that are primarily focused on the immunotherapy and alternative treatment of late stage cancer. In addition, the company intends to acquire innovative products for the treatment of late stage cancer. In this regard, the company primarily focuses on immunotherapy and alternative product candidates that are undergoing or have already completed significant clinical testing for the treatment of late stage cancer.
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.